Telo Genomics Corp (TELO) Price & Analysis

Compare

21 Followers

TELO Stock Chart & Stats

C$0.04

C$0.01(8.00%)

At close: Jan 07 4:00 PM EST

C$0.04

C$0.01(8.00%)

Day’s Range― - ―

52-Week RangeC$0.04 - C$0.13

Previous CloseN/A

Volume60.50K

Average Volume (3M)29.30K

Market Cap

C$5.02M

Enterprise ValueC$5.13M

Total Cash (Recent Filing)C$50.11K

Total Debt (Recent Filing)C$161.31K

Price to Earnings (P/E)―

Beta0.62

Next Earnings

Jun 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding100,430,470

10 Day Avg. Volume22,350

30 Day Avg. Volume29,304

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)18.74

Price to Sales (P/S)0.00

P/FCF Ratio-4.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Telomere PlatformA differentiated single‑chromosome telomere measurement capability is a durable technical advantage in diagnostics and research. It creates a barrier to entry, supports specialized use cases in oncology and aging, and underpins long‑term product relevance across clinical and research markets.

Low Absolute DebtVery low reported debt limits interest and refinancing burdens, preserving flexibility for an early‑stage biotech. With minimal interest exposure the company can prioritize R&D or commercialization spending without servicing large debt, reducing short‑term solvency pressure.

Improving Cash Burn TrendA reduction in TTM operating and free cash flow losses versus the prior year signals better expense control or operational efficiency. While still cash‑negative, an improving burn rate extends runway and lowers immediate financing frequency, aiding longer‑term execution on commercialization plans.

Bears Say

No RevenueAbsence of commercial revenue prevents validation of the business model and means margins are untested. Long‑term value depends on successful product commercialization; without sales, the company remains dependent on external capital and faces execution risk to convert technology into recurring revenue.

Persistent Operating LossesSustained multi‑period net losses erode cash reserves and shareholder equity, increasing the need for financing. Chronic losses raise execution and viability risks for an early‑stage biotech, potentially forcing strategic tradeoffs between R&D, commercial investment, and dilution.

Negative Equity / Dilution RiskA stockholders' deficit is a structural balance‑sheet weakness that undermines creditor and partner confidence. Negative equity heightens the probability of future equity raises or dilutive financing, which can alter capital structure and impair long‑term shareholder value.

Telo Genomics Corp News

Telo Genomics Raises $1.39 Million in Final Convertible Debenture Tranche

An announcement from Telo Genomics Corp ( ($TSE:TELO) ) is now available. Telo Genomics Corp. has closed the...

7d ago

Telo Genomics Upsizes Convertible Debenture Financing to $1.6 Million

The latest announcement is out from Telo Genomics Corp ( ($TSE:TELO) ). Telo Genomics Corp. has increased its...

17d ago

Telo Genomics Raises $840,000 in First Tranche of Convertible Debenture Financing

Telo Genomics Corp ( ($TSE:TELO) ) has shared an announcement. Telo Genomics Corp. has closed the first tranche...

26d ago

Telo Genomics Strengthens Finance Team With Appointment of Veteran CFO John Price

Telo Genomics Corp ( ($TSE:TELO) ) has issued an update. Telo Genomics Corp. has appointed John Price as...

2M ago

Telo Genomics Seeks Up to $1.2 Million via Convertible Debenture Financing

Telo Genomics Corp ( ($TSE:TELO) ) has shared an update. Telo Genomics Corp. has launched a non-brokered private...

2M ago

Telo Genomics Expands Multiple Myeloma MRD Validation with University of Athens Study

Telo Genomics Corp ( ($TSE:TELO) ) just unveiled an update. Telo Genomics has launched a retrospective, blood-based multiple...

3M ago

Telo Genomics Unveils Innovative Myeloma Testing at ASH Meeting

Telo Genomics Corp ( ($TSE:TELO) ) just unveiled an announcement. Telo Genomics Corp. presented its innovative approach to...

3M ago

Telo Genomics Unveils Advanced MRD Technology at Myeloma Summit

Telo Genomics Corp ( ($TSE:TELO) ) has issued an announcement. Telo Genomics Corp. announced its participation in the...

4M ago

Telo Genomics’ MRD Technology Gains Recognition at ASH 2025

Telo Genomics Corp ( ($TSE:TELO) ) has provided an update. Telo Genomics announced that its abstract on telomere-based...

5M ago

Telo Genomics Expands with New Toronto Facility and Board Update

The latest update is out from Telo Genomics Corp ( ($TSE:TELO) ). Telo Genomics Corp has relocated its...

6M ago

TELO FAQ

What was Telo Genomics Corp’s price range in the past 12 months?

Telo Genomics Corp lowest stock price was C$0.04 and its highest was C$0.13 in the past 12 months.

What is Telo Genomics Corp’s market cap?

Telo Genomics Corp’s market cap is C$5.02M.

When is Telo Genomics Corp’s upcoming earnings report date?

Telo Genomics Corp’s upcoming earnings report date is Jun 02, 2026 which is in 78 days.

How were Telo Genomics Corp’s earnings last quarter?

Telo Genomics Corp released its earnings results on Mar 02, 2026. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.

Is Telo Genomics Corp overvalued?

According to Wall Street analysts Telo Genomics Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Telo Genomics Corp pay dividends?

Telo Genomics Corp does not currently pay dividends.

What is Telo Genomics Corp’s EPS estimate?

Telo Genomics Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Telo Genomics Corp have?

Telo Genomics Corp has 100,430,470 shares outstanding.

What happened to Telo Genomics Corp’s price movement after its last earnings report?

Telo Genomics Corp reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Telo Genomics Corp?

Currently, no hedge funds are holding shares in TSE:TELO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Telo Genomics Corp

Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.